All articles by surya akella

Enanta secures FDA fast track designation for EDP-323 to treat RSV

EDP-323 showed reduction in RSV replication with potency in primary human bronchial epithelial cells against RSV A and B.

Leading clinical trials companies in the artificial intelligence theme